ArticleJournal of gastrointestinal cancer2026
Relative Dose Intensity and Clinical Outcomes of Using Trifluridine/Tipiracil with or without Bevacizumab in Patients Aged ≥ 75 Years with Advanced or Recurrent Colorectal Cancer: a Single-Center Retrospective Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvidence regarding treatment intensity, tolerability, and outcomes of using trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BV) in older patients with metastatic colorectal cancer (mCRC) is limited. We compared relative dose intensity (RDI), toxicity, and survival between FTD/TPI monotherapy and FTD/TPI plus BV, and examined the relationship between RDI and overall survival (OS) in older patients.
methodsIn this single-center retrospective study, patients aged ≥ 75 years with unresectable or recurrent mCRC who received FTD/TPI monotherapy or FTD/TPI plus BV were included. The primary endpoint was RDI; secondary endpoints included treatment exposure, adverse events, achieving RDI ≥ 80%, and OS. Landmark analysis at two treatment cycles and multivariable Cox regression were used to assess the independent effect of the RDI on OS.
resultsForty-nine patients were included. Median FTD/TPI RDI was 72.9% in the monotherapy group and 74.8% in the combination therapy group, with no significant difference in the proportion achieving an RDI ≥ 80%. Grade ≥ 3 neutropenia occurred in 60.5% of patients in the monotherapy group and 81.8% of patients in the combination therapy group. Hypertension and proteinuria were more frequent in the combination therapy group. Median OS was longer in the combination therapy group (18.3 vs. 8.3 months). RDI ≥ 80% was not associated with OS in landmark or Cox regression analyses. Age and baseline hemoglobin levels were independent prognostic factors.
conclusionsFTD/TPI monotherapy and FTD/TPI + BV had similar RDI but different toxicity profiles. RDI ≥ 80% did not independently predict OS. In older patients with mCRC, treatment selection, tolerability, and patient-specific factors may be more important than strict dose intensity. These findings suggest that individualized treatment strategies may be important, although further prospective studies are warranted.
Indexed as
Identifiers
42599544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.